As of 2024-12-12, the Intrinsic Value of GlaxoSmithKline PLC (GSK.L) is
1,967.32 GBP. This GSK.L valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 1,340.50 GBP, the upside of GlaxoSmithKline PLC is
46.80%.
The range of the Intrinsic Value is 1,611.03 - 2,503.94 GBP
1,967.32 GBP
Intrinsic Value
GSK.L Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
1,611.03 - 2,503.94 |
1,967.32 |
46.8% |
| DCF (Growth 10y) |
1,955.85 - 2,948.04 |
2,353.66 |
75.6% |
| DCF (EBITDA 5y) |
1,532.58 - 2,448.93 |
1,789.09 |
33.5% |
| DCF (EBITDA 10y) |
1,842.85 - 2,806.21 |
2,139.73 |
59.6% |
| Fair Value |
2,475.49 - 2,475.49 |
2,475.49 |
84.67% |
| P/E |
1,687.29 - 3,755.89 |
2,706.79 |
101.9% |
| EV/EBITDA |
1,379.13 - 4,578.88 |
2,934.47 |
118.9% |
| EPV |
1,144.25 - 1,550.73 |
1,347.49 |
0.5% |
| DDM - Stable |
639.58 - 1,227.57 |
933.57 |
-30.4% |
| DDM - Multi |
1,225.03 - 1,793.85 |
1,453.37 |
8.4% |
GSK.L Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
54,597.62 |
| Beta |
0.82 |
| Outstanding shares (mil) |
40.73 |
| Enterprise Value (mil) |
68,578.63 |
| Market risk premium |
5.98% |
| Cost of Equity |
10.05% |
| Cost of Debt |
4.35% |
| WACC |
8.52% |